205 related articles for article (PubMed ID: 10522716)
1. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA.
Rosengart TK; Lee LY; Patel SR; Kligfield PD; Okin PM; Hackett NR; Isom OW; Crystal RG
Ann Surg; 1999 Oct; 230(4):466-70; discussion 470-2. PubMed ID: 10522716
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease.
Rosengart TK; Lee LY; Patel SR; Sanborn TA; Parikh M; Bergman GW; Hachamovitch R; Szulc M; Kligfield PD; Okin PM; Hahn RT; Devereux RB; Post MR; Hackett NR; Foster T; Grasso TM; Lesser ML; Isom OW; Crystal RG
Circulation; 1999 Aug; 100(5):468-74. PubMed ID: 10430759
[TBL] [Abstract][Full Text] [Related]
3. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121.
Lee LY; Patel SR; Hackett NR; Mack CA; Polce DR; El-Sawy T; Hachamovitch R; Zanzonico P; Sanborn TA; Parikh M; Isom OW; Crystal RG; Rosengart TK
Ann Thorac Surg; 2000 Jan; 69(1):14-23; discussion 23-4. PubMed ID: 10654479
[TBL] [Abstract][Full Text] [Related]
4. Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121.
Patel SR; Lee LY; Mack CA; Polce DR; El-Sawy T; Hackett NR; Ilercil A; Jones EC; Hahn RT; Isom OW; Rosengart TK; Crystal RG
Hum Gene Ther; 1999 May; 10(8):1331-48. PubMed ID: 10365664
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of therapeutic angiogenesis from direct myocardial administration of an adenoviral vector expressing vascular endothelial growth factor 165.
Zhang D; Gai L; Fan R; Dong W; Wen Y
Chin Med J (Engl); 2002 May; 115(5):643-8. PubMed ID: 12133527
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease.
Rosengart TK; Bishawi MM; Halbreiner MS; Fakhoury M; Finnin E; Hollmann C; Shroyer AL; Crystal RG
Hum Gene Ther; 2013 Feb; 24(2):203-8. PubMed ID: 23137122
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure.
Leotta E; Patejunas G; Murphy G; Szokol J; McGregor L; Carbray J; Hamawy A; Winchester D; Hackett N; Crystal R; Rosengart T
J Thorac Cardiovasc Surg; 2002 Jun; 123(6):1101-13. PubMed ID: 12063456
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus vector-mediated transfer of the vascular endothelial growth factor cDNA to healing abdominal fascia enhances vascularity and bursting strength in mice with normal and impaired wound healing.
Ailawadi M; Lee JM; Lee S; Hackett N; Crystal RG; Korst RJ
Surgery; 2002 Feb; 131(2):219-27. PubMed ID: 11854705
[TBL] [Abstract][Full Text] [Related]
9. Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes.
Ben-Gary H; McKinney RL; Rosengart T; Lesser ML; Crystal RG
Mol Ther; 2002 Aug; 6(2):287-97. PubMed ID: 12349828
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous surgical revascularization and angiogenic gene therapy in diffuse coronary artery disease.
Huwer H; Welter C; Ozbek C; Seifert M; Straub U; Greilach P; Kalweit G; Isringhaus H
Eur J Cardiothorac Surg; 2001 Dec; 20(6):1128-34. PubMed ID: 11717016
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.
Rajagopalan S; Shah M; Luciano A; Crystal R; Nabel EG
Circulation; 2001 Aug; 104(7):753-5. PubMed ID: 11502697
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis.
Lazarous DF; Shou M; Stiber JA; Hodge E; Thirumurti V; Gonçalves L; Unger EF
Cardiovasc Res; 1999 Nov; 44(2):294-302. PubMed ID: 10690306
[TBL] [Abstract][Full Text] [Related]
13. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Hedman M; Hartikainen J; Syvänne M; Stjernvall J; Hedman A; Kivelä A; Vanninen E; Mussalo H; Kauppila E; Simula S; Närvänen O; Rantala A; Peuhkurinen K; Nieminen MS; Laakso M; Ylä-Herttuala S
Circulation; 2003 Jun; 107(21):2677-83. PubMed ID: 12742981
[TBL] [Abstract][Full Text] [Related]
14. Electromagnetic guidance for catheter-based transendocardial injection: a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models.
Kornowski R; Leon MB; Fuchs S; Vodovotz Y; Flynn MA; Gordon DA; Pierre A; Kovesdi I; Keiser JA; Epstein SE
J Am Coll Cardiol; 2000 Mar; 35(4):1031-9. PubMed ID: 10732905
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease.
Symes JF; Losordo DW; Vale PR; Lathi KG; Esakof DD; Mayskiy M; Isner JM
Ann Thorac Surg; 1999 Sep; 68(3):830-6; discussion 836-7. PubMed ID: 10509970
[TBL] [Abstract][Full Text] [Related]
16. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart.
Mack CA; Patel SR; Schwarz EA; Zanzonico P; Hahn RT; Ilercil A; Devereux RB; Goldsmith SJ; Christian TF; Sanborn TA; Kovesdi I; Hackett N; Isom OW; Crystal RG; Rosengart TK
J Thorac Cardiovasc Surg; 1998 Jan; 115(1):168-76; discussion 176-7. PubMed ID: 9451061
[TBL] [Abstract][Full Text] [Related]
17. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.
Harvey BG; Hackett NR; El-Sawy T; Rosengart TK; Hirschowitz EA; Lieberman MD; Lesser ML; Crystal RG
J Virol; 1999 Aug; 73(8):6729-42. PubMed ID: 10400771
[TBL] [Abstract][Full Text] [Related]
18. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study.
Mäkinen K; Manninen H; Hedman M; Matsi P; Mussalo H; Alhava E; Ylä-Herttuala S
Mol Ther; 2002 Jul; 6(1):127-33. PubMed ID: 12095313
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results.
Lathi KG; Vale PR; Losordo DW; Cespedes RM; Symes JF; Esakof DD; Maysky M; Isner JM
Anesth Analg; 2001 Jan; 92(1):19-25. PubMed ID: 11133594
[TBL] [Abstract][Full Text] [Related]
20. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.
Harvey BG; Maroni J; O'Donoghue KA; Chu KW; Muscat JC; Pippo AL; Wright CE; Hollmann C; Wisnivesky JP; Kessler PD; Rasmussen HS; Rosengart TK; Crystal RG
Hum Gene Ther; 2002 Jan; 13(1):15-63. PubMed ID: 11779412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
